ADMP - Adamis Pharmaceuticals: Preparing For Another Round Of Success Failure Then Hope

• Adamis Pharmaceuticals has two intramuscular injection rescue products approved by the FDA, SYMJEPI, and ZIMHI. In addition, the company's COVID-19 candidate, TEMPOL, has shown incredible promise thus far.
• Despite hitting their objectives and making significant progress, these efforts didn’t move the needle in the positive direction for earnings and the share price.
• The company has a history of making progress but they fail to capitalize on that progress. Yet, they still find another opportunity to be a source of hope for investors.
• I am going to hold off on accumulating more shares at these levels and will switch to a discounted valuation to determine my buy target. I reveal my new buy target.
• I am still looking to hold my ADMP shares and the ticker will remain in Compounding Healthcare’s Bio Boom Portfolio for the foreseeable future.

For further details see: